Article

Brolucizumab noninferior to aflibercept for treating DME with few injections

Author(s):

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema.

Dilsher Dhoot, MD, reports results of the KESTREL and KITE trials, in which brolucizumab was compared with aflibercept for treating diabetic macular edema

Reviewed by Dilsher Dhoot, MD

The KESTREL and KITE studies compared brolucizumab (Beovue, Novartis) with aflibercept (Eylea, Genentech Inc.) for treating diabetic macular edema (DME).

During the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dilsher Dhoot, MD, from California Retina Consultants, Santa Barbara, California, reported results from the studies, including several key take-home points. 

Brolucizumab 6 mg met the primary study endpoint of noninferiority to aflibercept regarding the mean change in the best-corrected visual acuity (BCVA) at week 52 with fewer injections.

More than half of the patients (55.1% in the KESTREL Study and 50.3% in the KITE) who received the 6-mg dose of brolucizumab maintained the VA on an every-12-week treatment interval up to week 52 immediately after they received the loading dose.

A median of 7 injections were administered to the patients treated with brolucizumab compared with 9 injections in the patients treated with aflibercept out to week 52.

Robust improvements were seen in the central subfield thickness from baseline with brolucizumab 6 mg. More patients on brolucizumab achieved a decrease in the central subfield thickness exceeding 280 µ at weeks 32 and 52.

More patients treated with brolucizumab 6 mg had overall resolution of intraretinal and subretinal fluid and resolution of intraretinal fluid at week 52.

Brolucizumab fared better than the 2 mg dose of aflibercept in the KITE study. In addition, the Diabetic Retinopathy Severity Scale score showed clinically relevant improvements at Week 52 compared with baseline, that is, 2 or more steps.

Brolucizumab demonstrated an overall favorable benefit/risk profile. The safety data from the KESTREL and KITE studies did not show that the underlying diabetes negatively impacted the brolucizumab-related incidence of intraocular inflammation.

This article is adapted from Dhoot’s Retina Subspecialty Day presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans. He is a consultant/advisor to Novartis.

See more AAO meeting coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.